SCHEMBL353101

SCHEMBL353101

CNC(=O)c1occc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.62
MAPT P10636 2/20 0.62
ALDH1A1 P00352 1/20 0.62
THRB P10828 1/20 0.62
MEN1 O00255 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
KMT2A Q03164 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
PKM P14618 1/20 0.51
NAMPT P43490 1/20 0.51
GAA P10253 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
GRM1 Q13255 9/20 0.46
GRM4 Q14833 5/20 0.43
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11908920 0.83 KDM4E (0.62) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL1902377 0.82 MAPT (0.66) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL26344762 0.82 MAPT (0.61) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL26332896 0.82 KDM4E (0.61) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL13753326 0.79 MAPT (0.72) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL28244480 0.79 KDM4E (0.57) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL13753382 0.79 KDM4E (0.57) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL10417495 0.78 KDM4E (0.55) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL22866139 0.78 HDAC8 (0.41) KDM4EMAPTALDH1A1THRBNPC1
SCHEMBL20687641 0.78 KDM4E (0.40) KDM4EMAPTALDH1A1THRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
CN-116669744-A Nrf2 activating compounds 千寿制药株式会社 2023-08-29 CN disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
CN-114080389-A Nrf2 activating compound 千寿制药株式会社 2022-02-22 CN disclosed
WO-2021002473-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2021-01-07 WO disclosed
CN-104945287-B A kind of synthetic method of the acid inner salt compound of amidine 苏州大学张家港工业技术研究院 2017-06-13 CN disclosed
CN-104961660-B A kind of acid inner salt compound of amidine 苏州大学张家港工业技术研究院 2017-06-13 CN disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
CN-1152908-A Phenyl acetic acid derivatives, process and intermediate products for their production and agents containing them BASF AG (DE) 1997-06-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 KDM4E 2390/4885MAPT 3128/4885ALDH1A1 555/4885
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA KDM4E 1862/4885MAPT 2275/4885ALDH1A1 2806/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 KDM4E 1987/4885MAPT 2863/4885ALDH1A1 790/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 KDM4E 3587/4885MAPT 2512/4885ALDH1A1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.